Cardio Diagnostics Holdings Inc Cash Flow Conversion Efficiency

Latest as of June 2026: -0.181x

Cardio Diagnostics Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cardio Diagnostics Holdings Inc (2020–2025)

Cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2025. This chart illustrates how Cardio Diagnostics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Cardio Diagnostics Holdings Inc for real-time trading data and today's change.

Cardio Diagnostics Holdings Inc Cash Flow Conversion Ratio Explained

Cardio Diagnostics Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cardio Diagnostics Holdings Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their cash flow conversion efficiency. Also see Cardio Diagnostics Holdings Inc stock valuation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
GIGLIO.COM S.P.A. O.N.
F:5JR0
N/A
WF Holding Limited Ordinary Shares
NASDAQ:WFF
N/A
PATRYS Ltd
AU:PAB
-2.365x
RealTech AG
XETRA:RTC
0.171x
Merino & Co. Ltd
AU:MNC
-0.297x
Elkop SA
WAR:EKP
0.020x
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
-0.167x
Jackpot Digital Inc
V:JJ
0.170x

Annual Cash Flow Conversion Efficiency for Cardio Diagnostics Holdings Inc (2020–2025)

The table below shows the annual cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2025. Review CDIO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $6.97 Million $-5.73 Million -0.821x -57.20%
2024-12-31 $9.56 Million $-4.99 Million -0.522x +72.76%
2023-12-31 $2.96 Million $-5.67 Million -1.917x -62.02%
2022-12-31 $4.30 Million $-5.09 Million -1.183x -115.97%
2021-12-31 $1.07 Million $-585.29K -0.548x -227.92%
2020-12-31 $60.37K $25.86K 0.428x --

About Cardio Diagnostics Holdings Inc

NASDAQ:CDIO USA Biotechnology
Market Cap
$5.59 Million
Market Cap Rank
#28383 Global
#5873 in USA
Share Price
$1.89
Change (1 day)
+1.07%
52-Week Range
$1.05 - $6.55
All Time High
$10.25
About

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more